Zhaoke Ophthalmology-B (06622.HK): Expands Collaboration Network to Advance Commercialization of Presbyopia New Drug BRIMOCHOL™ PF in Asian Markets

NewTimeSpace News: On the 26th, Zhaoke Ophthalmology Limited (06622.HK) released a voluntary announcement, declaring that it has secured two important collaborations in the Asian market to drive the commercialization of its core investigational drug BRIMOCHOL™ PF.

Pursuant to the announcement, the Company has expanded its existing partnership agreement with AFT Pharmaceuticals Limited, a leading medical product manufacturer and distributor, granting it theexclusive distribution rightsfor the drug in the Singapore market. Meanwhile, the Company has also established a new strategic partnership with Santen Pharmaceutical Co., Ltd., a leading Japanese ophthalmology company, awarding it the exclusive distribution rights in the Vietnam market. The two partners will be responsible for the drug’s registration, importation, promotion, distribution, marketing and sales in their respective markets.

BRIMOCHOL™ PF is apreservative-free, once-daily investigational eye dropindicated for the correction of lost near vision due to presbyopia. It is a core investigational asset of Zhaoke Ophthalmology, licensed in from its partner Tenpoint Therapeutics.

The regulatory progress of the drug in the U.S. has attracted much attention. The U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and set thePDUFA datefor January 28, 2026. The expansion of these collaborations is intended to pave the way for the future launch of the drug in key Asian markets.

Zhaoke Ophthalmology cautioned that there is no guarantee that the drug will ultimately be successfully developed or commercialized, and shareholders and investors are advised to exercise extreme caution when dealing in the Company’s shares.